1968 Dongkook pharmaceutical Co., Ltd. is established.
1988 The first GMP factory is constructed.
1989 The Dongkook R&D Center is established.
1992 The second GMP factory is constructed.
1994 The third GMP factory is constructed.
1995 “Minocline Strip” is awarded KT (the excellent Korean Technology) stamp by the
Ministry of Science and Technology
1996 “Pofol Injection” is awarded KT stamp
1997 Dongkook is selected as a ‘Company of Superior Patents Management’ by the
Ministry of Commerce.
1999 Dongkook is awarded a Citation by
2004 the Ministry of Commerce for generating significant export to new markets.
Dongkook has been concentrating on R&D and technical innovation since its establishment in 1968.
Since 1989, Dongkook’s active R&D Center has been not only working toward the development of new
drugs but also studying in collaboration with local universities and foreign research centers. In the
ongoing efforts, Dongkook has developed Minocline Strip, a brand-new medication for periodontitis that
utilizes Local Drug Delivery System techniques and also has succeeded to produce Pofol, a superior
intravenous general anesthetics.
These innovative products were approved as the excellent Korean Technology domestically in 1995 and
in 1996, respectively. Recently, Dongkook has developed Streptokinase(thrombolytic agent), Lorelin
depot(anticancer agent) and Pamiray(X-ray contrast medium of Iopamidol). Dongkook is particularly
proud of the recognition given to the quality of Iopamidol, which was certified by the EDQM(European
Department for the Quality of Medicines) in 2000.
Projects under development
·Recombinant peptide hormone for osteoporosis
·Recombinant protein for thrombosis
·Immunosuppressants isolated from microbes
Organic Synthesis division
·Cilastatin, a beta-lactamase inhibitor
·Therapeutic agents for Alzheimer disease
·Derivatives of asiaticoside for wou